Holen Sie sich die Stockscreener-App
0.4341
0.05%
0.000100
Schlusskurs vom Vortag:
$0.434
Offen:
$0.4469
24-Stunden-Volumen:
165.35K
Relative Volume:
0.03
Marktkapitalisierung:
$1.58M
Einnahmen:
$4.49M
Nettoeinkommen (Verlust:
$-10.97M
KGV:
-0.0712
EPS:
-6.0969
Netto-Cashflow:
$-7.17M
1W Leistung:
-20.64%
1M Leistung:
-0.18%
6M Leistung:
-79.42%
1J Leistung:
-88.87%
1-Tages-Spanne:
$0.4251
$0.4598
1-Wochen-Bereich:
$0.4239
$0.5471
52-Wochen-Spanne:
$0.3144
$4.85
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Firmenname
Ensysce Biosciences Inc
Sektor
Branche
Telefon
(858) 263-4196
Adresse
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.4342 | 1.58M | 4.49M | -10.97M | -7.17M | -6.0969 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.38 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.20 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
704.81 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.33 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.55 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ensysce Biosciences Inc Aktie (ENSC) Neueste Nachrichten
Risk Analysis: Is Ensysce Biosciences Inc being accumulated by smart money2026 Setups & Daily Profit Focused Screening - baoquankhu1.vn
Ensysce Biosciences Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Market Fear: Will Ensysce Biosciences Inc benefit from geopolitical trendsJuly 2025 Setups & Smart Swing Trading Alerts - baoquankhu1.vn
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Pl - PharmiWeb.com
CEO takes live questions on Ensysce PF614 pain-drug plans - Stock Titan
Ensysce publishes phase 1 data on overdose-limiting opioid tech By Investing.com - Investing.com Australia
ENSC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
Ensysce publishes phase 1 data on overdose-limiting opioid tech - Investing.com India
New opioid design limits drug release when too many pills are swallowed - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Promising Penny Stocks To Add to Your Watchlist – March 1st - Defense World
Dow Dips Over 600 Points; US Producer Prices Increase In January - Sahm
Top Penny Stocks To Follow TodayFebruary 27th - MarketBeat
Ensysce Biosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Ensysce Biosciences (ENSC) over sub-$1 minimum bid price - Stock Titan
Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Benzinga
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - Corsicana Daily Sun
Opioid safety drug developer Ensysce explores deals, possible asset sales - Stock Titan
Market Overview: Is Ensysce Biosciences Inc subject to activist investor interest2025 Market Outlook & Weekly Watchlist of Top Performers - baoquankhu1.vn
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events - Corsicana Daily Sun
Drug developer Ensysce invited to 2026 pain and substance use research forums - Stock Titan
Can Ensysce Biosciences Inc. continue delivering strong returnsJuly 2025 Momentum & Reliable Entry Point Alerts - mfd.ru
Ensysce Biosciences files to sell 29.47M shares of common stock for holders - Intellectia AI
Why Ensysce Biosciences Inc. stock remains a top recommendationDip Buying & Free Community Consensus Stock Picks - mfd.ru
Why Ensysce Biosciences Inc. stock is a must watch in 2025Trade Entry Report & Daily Volume Surge Trade Alerts - mfd.ru
Is Ensysce Biosciences Inc. subject to activist investor interestQuarterly Performance Summary & Verified Technical Signals - mfd.ru
RSI Check: Will Ensysce Biosciences Inc benefit from geopolitical trends2025 Trading Volume Trends & Weekly Sector Rotation Insights - baoquankhu1.vn
Ensysce Biosciences Reaches 50% Enrollment Milestone In Pivotal Phase 3 Trial Of PF614 - Nasdaq
Ensysce Biosciences reaches 50% enrollment in Phase 3 pain drug trial - Investing.com Nigeria
Does Ensysce Biosciences Inc. meet Warren Buffett’s criteriaEarnings Risk Summary & Capital Efficient Trade Techniques - mfd.ru
Ensysce Biosciences CEO says 'positioned for continued momentum' - MSN
Ensysce Biosciences reaches 50% enrollment in Phase 3 pain drug trial By Investing.com - Investing.com South Africa
New Highs: Does JPMPRM outperform in volatile marketsTrade Volume Report & Stock Timing and Entry Methods - baoquankhu1.vn
Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics | DelveInsight - GlobeNewswire Inc.
Ensysce Flat on Review News - Baystreet.ca
Opioid designed to stay inactive until swallowed hits Phase 3 milestone - stocktitan.net
Rate Hike: Will The Western Union Company benefit from geopolitical trendsBond Market & Fast Gain Stock Tips - baoquankhu1.vn
Merger Talk: Is Ensysce Biosciences Inc stock showing strong momentumQuarterly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Ensysce Biosciences receives patent allowance in Brazil for pain tech By Investing.com - Investing.com Canada
Ensysce Biosciences receives patent allowance in Brazil for pain tech - Investing.com
New Brazil patent backs Ensysce bid for safer opioid pain drugs - Stock Titan
Volume Recap: Is Ensysce Biosciences Inc stock dividend yield sustainableTrade Exit Report & Low Risk High Win Rate Picks - Bộ Nội Vụ
Panic Selling: Why Ensysce Biosciences Inc. stock is seen as undervaluedJuly 2025 Big Picture & Detailed Earnings Play Strategies - Bộ Nội Vụ
What sentiment indicators say about Ensysce Biosciences Inc. stockBreakout Watch & Stock Portfolio Risk Management - ulpravda.ru
Ensysce Biosciences Annual Meeting: Share Issuance Approved, PF614 Phase III and FDA Designations Update - Defense World
Why Ensysce Biosciences Inc. stock is seen as undervaluedJuly 2025 Sector Moves & AI Based Trade Execution Alerts - Улправда
Why Ensysce Biosciences Inc. stock could be next big winnerWeekly Trade Report & AI Forecasted Stock Moves - Улправда
Ensysce Biosciences Shareholders Approve Key Corporate Actions - TipRanks
How Ensysce Biosciences Inc. stock compares to growth peersWeekly Gains Report & Safe Capital Growth Stock Tips - Улправда
How rising interest rates impact Ensysce Biosciences Inc. stockJuly 2025 Setups & Daily Technical Forecast Reports - Улправда
Finanzdaten der Ensysce Biosciences Inc-Aktie (ENSC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):